不同剂量瑞舒伐他汀对老年冠心病合并高脂血症患者的疗效分析

Clinical Effect of Different Doses of Rosuvastatin in the Treatment of Coronary Heart Disease and Hyperlipidemias in the Elderly Patients

目的通过比较不同剂量瑞舒伐他汀治疗老年冠心病（coronary heart disease，CHD）合并高脂血症（hyperlipidemia，HLP）的临床效果，探讨瑞舒伐他汀治疗老年冠心病合并高脂血症的最适剂量。方法选择同期门诊治疗的冠心病合并高脂血症老年患者92例，随机均分为小剂量组与大剂量组，两组患者在常规治疗基础止，小剂量组给予瑞舒伐他汀10mg／d，大剂量组给予瑞舒伐他汀20mg／d，比较两组患者治疗4．周与12周后临床效果及不良反应情况。结果早期治疗时，大剂量的临床效果显著优于小剂量治疗的临床效果（P〈0．05）；后期大剂量的临床效果与小剂量治疗的临床效果无显著差异（P〉0．05）；瑞舒伐他汀治疗过程中不良反应少且轻微。结论瑞舒伐他汀治疗老年冠心病合并高脂血症患者时，早期应采用大剂量治疗，后期应采用小剂量治疗，瑞舒伐他汀的临床疗效确切，安全可靠。

Objective To compare the effect of different doses of rosuvastatin in the treatment of coronary heart disease （CHD） and HLP in the elderly patients and explore the optimum dose of rosuvastatin in the treatment. Methods 92 elderly patients with hypertension and hypedipidemias were selected and were randomly divided into low dose of rosuvastatin group and high dose of ro- suvastatin group. Low dose group received 10 mg/d and high dose group accepted 20 mg/d. The clinical effects and adverse reactions after 4 weeks＇ and 12 weeks＇ treatment in two groups were compared. Results In the early stage of treatment the clinical effect in high does group was better than that in low dose group （ P 〈 0. 05 ）. There was no significant difference in the clinical effect between high does group and low dose group （ P 〈 0. 05 ） in the late stage of treatment. Adversb reactions were mild during the treatment. Conclusion The study shows when using rosuvastatin in the treatment of CHD and HLP in the elderly, in the early stage of treatment high dose of rosuvastatin should be used and in the late stage of treatment small dose of it Would be taken. Rosuvastatin is safe and reliable in the treatment of CHD and HLP in the elderly.